Dr. Reddy's Laboratories Ltd. · DRREDDY
Every Dr. Reddy's Laboratories Ltd. result whose ten-session window has closed, judged against the last read made before it. Sector index NIFTY PHARMA. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
24results judged
2read right
1read wrong
2flat / no call
19unread
33%beat the market
-1.5%avg vs market, 10d
4.2%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| neutral | 1 | 0 | 0 | 1 | — | +3.2% | |
| unfavourable | 1 | 1 | 0 | 0 | 100% | -5.2% | |
| weak | 3 | 1 | 1 | 1 | 50% | +1.0% | |
| unread | 19 | 0 | 0 | 0 | — | -1.9% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
24 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 22 Jul Q1FY27 | weak | right | -2.6% | -1.0% | -3.7% | -7% | no figures |
|
› |
| 12 May Q4FY26 | weak | neutral | +2.6% | +3.9% | +1.6% | — | no figures |
|
› |
| 21 Jan Q3FY26 | weak | wrong | +6.8% | +7.3% | +5.1% | -7% | no figures |
|
› |
| 24 Oct Q2FY26 | unfavourable | right | +0.5% | -5.6% | -5.2% | -2% | no figures |
|
› |
| 9 May Q4FY25 | neutral | neutral | +4.4% | +7.4% | +3.2% | -4% | no figures |
|
› |
| 24 Jan Q3FY25 | — | unread | -7.1% | -3.8% | -5.3% | +4% | no figures |
|
› |
| 5 Nov Q2FY25 | — | unread | +1.2% | -6.0% | -2.5% | -81% | no figures |
|
› |
| 27 Jul Q1FY25 | — | unread | -1.1% | +0.1% | +2.1% | +14% | no figures |
|
› |
| 7 May Q4FY24 | — | unread | -6.1% | -5.8% | -8.7% | +2% | no figures |
|
› |
| 30 Jan Q3FY24 | — | unread | +2.6% | +7.1% | +5.7% | +4% | no figures |
|
› |
| 27 Oct Q2FY24 | — | unread | -0.6% | +0.5% | -1.5% | -5% | no figures |
|
› |
| 26 Jul Q1FY24 | — | unread | +2.0% | +6.9% | +8.0% | +16% | no figures |
|
› |
| 10 May Q4FY23 | — | unread | -8.2% | -7.5% | -7.5% | +9% | no figures |
|
› |
| 25 Jan Q3FY23 | — | unread | +3.0% | +7.1% | +7.3% | -7% | no figures |
|
› |
| 29 Oct Q2FY23 | — | unread | +1.7% | -0.6% | -4.1% | +6% | no figures |
|
› |
| 28 Jul Q1FY23 | — | unread | -3.5% | +0.9% | -4.4% | -1% | no figures |
|
› |
| 19 May Q4FY22 | — | unread | +8.8% | +10.4% | +5.5% | -9% | no figures |
|
› |
| 28 Jan Q3FY22 | — | unread | +1.1% | +1.6% | +0.1% | -7% | no figures |
|
› |
| 29 Oct Q2FY22 | — | unread | +1.9% | +3.4% | +1.5% | -6% | no figures |
|
› |
| 27 Jul Q1FY22 | — | unread | -12.6% | -11.9% | -14.7% | -1% | no figures |
|
› |
| 14 May Q4FY21 | — | unread | -1.0% | -2.0% | -7.0% | +21% | no figures |
|
› |
| 29 Jan Q3FY21 | — | unread | -9.1% | -1.6% | -11.4% | -3% | no figures |
|
› |
| 28 Oct Q2FY21 | — | unread | -1.3% | -2.5% | -10.7% | +7% | no figures |
|
› |
| 29 Jul Q1FY21 | — | unread | +11.5% | +11.5% | +11.5% | +1% | no figures |
|
› |